Status of COVID-19 vaccine development

Tidsskr Nor Laegeforen. 2020 Sep 9;140(13). doi: 10.4045/tidsskr.20.0676. Print 2020 Sep 29.
[Article in English, Norwegian]
No abstract available

Plain language summary

The pandemic caused by SARS-CoV-2 has created a global humanitarian and economic crisis for which there is currently no solution in sight. Much hope has therefore been pinned on a vaccine that can protect against the disease COVID-19. As of August 2020, the World Health Organization has registered 173 vaccine candidates as being in development. Six candidates have entered phase 3 trials, and the first results from these are expected in the autumn.

MeSH terms

  • Antigens, Viral / immunology
  • Betacoronavirus
  • COVID-19
  • COVID-19 Vaccines
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Humans
  • Pandemics / prevention & control*
  • Pneumonia, Viral / prevention & control*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / immunology
  • Viral Vaccines / immunology*

Substances

  • Antigens, Viral
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike protein, SARS-CoV-2